Award
Delivery Order #75N93025F00001
SRI International Wins Contract for Non-Clinical Drug Studies
Buyer
National Institutes of Health
Award Amount
$3,626,906.00
Ceiling
$3,626,906.00
Awarded
July 25, 2025
Period of Performance
Jul 25, 2025 – Jul 20, 2027
Identifier
75N93025F00001
NAICS
541715
This award represents a definitive delivery order granted to SRI International, a prominent nonprofit research and development organization renowned for its innovations in scientific research. The contract focuses on conducting essential non-clinical studies that support Investigational New Drug (IND), New Drug Applications (NDA), and Biologics License Applications (BLA), a critical component in the pharmaceutical approval processes. Its significance lies in enhancing the efficiency of drug development, thus contributing positively to public health outcomes. The scope of work includes a systematic approach to non-clinical testing to ensure regulatory compliance for new drug submissions, set to occur over a multi-year period from mid-2025 to mid-2027. This contract was awarded through a competitive bidding process, showcasing SRI International's proven capabilities in the field. Notably, this is a continuation of their previous collaborative work under an indefinite delivery indefinite quantity (IDIQ) contract, demonstrating their ongoing expertise in healthcare-related research. This award marks a substantive advancement in pharmaceutical development and public health research.
Description
NON-CLINICAL STUDIES IN SUPPORT OF IND/NDA/BLA SUBMISSIONS